Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $117.30 Average Price Target from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $117.30.

A number of research firms recently commented on DNTH. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a report on Monday, March 9th. Oppenheimer raised their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 9th. Wedbush raised their target price on Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Finally, William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Monday, March 16th.

Dianthus Therapeutics Trading Up 3.6%

NASDAQ DNTH opened at $82.45 on Friday. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $88.02. The firm’s fifty day simple moving average is $59.56 and its 200-day simple moving average is $45.99. The company has a market capitalization of $3.67 billion, a PE ratio of -20.11 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In other news, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marino Garcia sold 122,918 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 200,430 shares of company stock worth $16,332,702. 8.15% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $43,000. Seven Fleet Capital Management LP bought a new position in Dianthus Therapeutics during the fourth quarter worth $604,000. Invesco Ltd. raised its stake in Dianthus Therapeutics by 125.9% during the 4th quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock valued at $4,182,000 after purchasing an additional 56,560 shares during the last quarter. XTX Topco Ltd acquired a new position in Dianthus Therapeutics during the 4th quarter valued at $550,000. Finally, Voloridge Investment Management LLC boosted its holdings in Dianthus Therapeutics by 80.5% in the 4th quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock valued at $1,627,000 after purchasing an additional 17,612 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.